Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.

IF 2.2 4区医学 Q3 ONCOLOGY Cancer Biomarkers Pub Date : 2024-03-20 DOI:10.3233/CBM-230301

Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura

{"title":"Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.","authors":"Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura","doi":"10.3233/CBM-230301","DOIUrl":null,"url":null,"abstract":"Background: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable.Objective: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples.Methods: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines.Results: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002).Conclusions: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-230301","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable.

Objective: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples.

Methods: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines.

Results: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002).

Conclusions: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

与 NSCLC 免疫检查点阻断剂联合化疗相关的外周血生物标志物。

背景：预测免疫检查点抑制剂（ICIs）和化疗联合治疗非小细胞肺癌（NSCLC）临床疗效的生物标志物很有价值：预测免疫检查点抑制剂（ICIs）和化疗联合治疗非小细胞肺癌（NSCLC）临床结果的生物标志物将非常有价值：本研究旨在利用外周血样本寻找非小细胞肺癌（NSCLC）患者对 ICI/化疗联合疗法反应的预测指标：纳入2019年7月至2021年5月期间诊断为晚期NSCLC并接受ICI/化疗联合治疗的患者，并评估部分应答（PR）、疾病稳定（SD）或疾病进展（PD）。我们测量了循环免疫细胞、血浆细胞因子和趋化因子：结果：共招募了 19 名患者。与 SD/PD 患者相比，PR 患者的循环自然杀伤（NK）细胞在 CD45 + 细胞中所占的比例、程序性死亡 1（PD-1）+ Tim-3 + T 细胞在 CD4 + 细胞中所占的比例以及血浆中趋化因子 C-X-C 配体（CXCL10）的含量均显著升高（中位数为 8.1%-vs-2.1%，P= 0.0032；中位数1.2%-vs-0.3%，P= 0.0050；中位数122.6 pg/ml-vs-76.0 pg/ml，P= 0.0125）。有2个或3个升高因子的患者的无进展生存期长于0个或仅有1个因子的患者（未达到-vs-5.6个月，P= 0.0002）：我们得出结论：治疗前外周血中的NK细胞、CD4 + PD-1 + Tim-3 + T细胞和CXCL10水平可预测ICI/化疗联合治疗NSCLC的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.